Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: April 17, 2025

Abstract Peptides are an emerging class of biologics for cancer immunotherapy; however, their clinical translation is hindered by poor binding kinetics, bioavailability, and short plasma half‐life compared to corresponding antibodies. Nanoparticles present potential solutions but face scale‐up difficulties due complexity. Here, a translatable, modular nanoparticle scaffold presented peptide‐based immune checkpoint inhibitors (ICIs). This platform based on simple structure generation 7 (G7) poly(amidoamine) (PAMAM) dendrimers conjugated with engineered peptides (dendrimer‐peptide conjugates, DPCs). DPCs functionalized multiple copies programmed death‐ligand 1 (PD‐L1)‐binding peptide exhibited significantly enhanced avidity‐based kinetics in vitro specificity, addition the substantially prolonged vivo. Notably, series vivo experiments revealed that displayed selective tumor accumulation high efficacy, without apparent toxicity, when applied syngeneic mouse model bearing oral carcinoma (MOC1) tumors. The results indicate DPC improves antagonistic effect behaviors PD‐L1‐binding peptides, which can be potentially virtually any ICIs. platform's simplicity nature will likely increase its ultimately enable precision/personalized immunotherapy.

Language: Английский

Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa

International Journal of Nanomedicine, Journal Year: 2024, Volume and Issue: Volume 19, P. 9843 - 9870

Published: Sept. 1, 2024

Evodiamine (EVO) is a tryptamine indole alkaloid and the main active ingredient in

Language: Английский

Dendrimer nanoplatforms for oral drug delivery applications

Journal of Pharmaceutical Investigation, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 26, 2024

Language: Английский